

Aggregation Behaviour of Peptide-Polymer Conjugates Containing Linear Peptide Backbones and Multiple Polymer Side Chains Prepared by Nitroxide-Mediated Radical Polymerization

Michael Möller,^a Carsten Hentschel,^b Lifeng Chi^b and Armido Studer*^a

^a *Organisch-Chemisches Institut and NRW Graduate School of Chemistry, Westfälische Wilhelms-Universität Münster, Corrensstraße 40, 48149 Münster (Germany). Fax: (+49)251-833-6523; Tel: (+49)251-833-3291; E-mail: studer@uni-muenster.de*

^b *Physikalisches Institut, Westfälische Wilhelms-Universität Münster, Wilhelm-Klemm-Straße 10, 48149 Münster (Germany). Fax: (+49)251-833-3602; Tel: (+49)251-833-3651; E-mail: chi@uni-muenster.de*

Supplementary Data

Contents

General	2
Synthetic procedures	4
Polymerization procedures	27
¹H-NMR and ¹³C-NMR spectra of new compounds	30
Polymerization results	45
Proof of livingness of polymerizations	47
DLS-data of peptide-PNIPAM conjugates	49
References	49

General

Reactions involving air or moisture sensitive starting materials, intermediates or products were performed in *Schlenk* flasks, which have been flame-dried in high vacuum and flushed with argon. CCl₄ (*Acros*), methanol (MeOH, 99.9 %, *Extra Dry, AcroSeal*®), DMSO (*Acros*) and acetic acid (HOAc, *Acros*) were used as received. Ethyl acetate (EtOAc) was distilled without drying reagent. All other solvents were freshly distilled under argon atmosphere or in vacuum from drying reagents. Benzene was distilled from Na, THF was distilled from Na/K, CH₂Cl₂ was distilled from P₂O₅, DMF was distilled from K₂CO₃ and ninhydrin, *N*-methylpyrrolidinone was distilled from CaH₂ and ninhydrin. Styrene was distilled from CaH₂ and *N*-isopropylacrylamide (NIPAM) was crystallized twice from *n*-pentane to remove stabilizers and stored at -30 °C under argon atmosphere. All other chemicals were used as received from the suppliers (*Acros, Aldrich, Bachem, Fluka*).

Solvents for flash column chromatography (FC), crystallizations and extractions have been distilled once, MTBE was previously dried over KOH. FC was performed using silica gel 60 (40-63 μm, *Merck*) applying an overpressure of up to 0.4 bar. Thin layer chromatography (TLC) was performed using silica gel 60 F₂₅₄ plates from *Merck*. Detection of the compounds was carried out by UV-light or dipping into solutions of KMnO₄ (1.5 g in 400 mL H₂O, 5 g NaHCO₃) or Ce(SO₄)₂·H₂O (10 g in 0.94 L H₂O, 60 mL *conc.* H₂SO₄, 25 g, phosphormolybdic acid hydrate). Reversed-phase flash chromatography (RP-FC) was performed using silica gel 90 C-18 reversed phase (40-63 μm, *Fluka*). Reversed-phase TLC was carried out using silica gel 60 RP-18 F₂₅₄S plates from *Merck* and substances were detected by UV-light (λ = 254 nm). Samples for spin-coating were dissolved with a concentration of 1 mg/mL. A droplet of 10 μL was spread on a silicon wafer and left for 20 seconds. Spin-coating was performed on a self-prepared spin-coating apparatus with a rotation speed of 5000 rounds per minute.


IR-spectra were recorded on a *Digilab Excalibur FTS 4000* device equipped with a *MKII Golden Gate Single Reflexion ATR System*. ¹H-NMR (300 and 400 MHz) and ¹³C-NMR (75 and 100 MHz) spectra were recorded on a *Bruker DPX-300*, a *Bruker ARX-300* or a *Bruker AMX-400* spectrometer at room temperature (rt). Chemical shifts in ppm are referenced to the solvent residue peaks (CHCl₃ at 7.26 ppm for ¹H-NMR and at 77.00 ppm for ¹³C-NMR;

CH₃OH at 4.87 ppm for ¹H-NMR and at 49.00 ppm for ¹³C-NMR) as internal standards. Mass spectrometry was performed on a *Bruker Daltonics MicroTof*, a *Waters-Micromass Quatro LCZ* or an *Orbitrap LTQ XL* for ESI-MS and HRMS. Elemental analyses were performed on a *Vario EL III (Elemental)*. Melting points were determined with a *Stuart SMP10* and are uncorrected.

Gel permeation chromatography (GPC) was performed on a system consisting of a *Knauer HPLC Pump 64* and a *Knauer Differential Refractometer* ($\lambda = 950 \pm 30$ nm). Analysis was carried out using *PSS WinGPC Compact V.720* software (Polymer Standards Service) based upon calibration with polystyrene standards (*Polymer Laboratories Polystyrene Medium MW Calibration Kit S-M-10*) or poly(methyl methacrylate) standards (*Polymer Laboratories Poly(methyl methacrylate) Medium MW Calibration Kit S-M-10*). Polystyrene chromatography was performed with a set of two *PLgel MIXED-C* columns (300 × 7.5 mm, particle size: 5 μm Polymer Laboratories, linear range of molecular weight: 200-2,000,000 g/mol) in THF (distilled over KOH and FeSO₄ and degassed by bubbling argon for at least 30 min). PNIPAM chromatography was carried out using a set of two *Shodex GPC KF-804L* columns (300 × 8 mm, particle size: 7 μm, range of molecular weight: < 400,000 (polystyrene)) in DMF (HPLC-grade, purchased by *Roth*, degassed by bubbling argon for at least 30 min) containing LiBr (c = 0.01 M) at 40 °C (warmed by an oven). Dynamic light scattering (DLS) measurements were performed on a *Malvern Zetasizer Nano ZEN 3600* and analyzed with *Malvern Zetasizer Nano* software, version 5.03. THF was purified as for GPC, water was purified as for HPLC. Atomic force microscopy (AFM) was performed on a *Park Systems XE-100* microscope in tapping mode at resonance frequency. The used cantilever was a rectangular silicon cantilever (PPP-NRHR-W) from *Nanosensors*. Typical tip radius was < 10 nm, typical force constant 42 N/m and typical resonance had a frequency of 330 KHz. Typical values were taken from data sheet.

Synthetic procedures

1-Bromo-4-(1-bromomethyl)-benzene (26)




1-Bromo-4-ethyl-benzene (14.0 mL, 101 mmol, 1.0 eq.) was dissolved in CCl_4 (100 mL). The solution was warmed to 50 °C and illuminated by a light bulb (*Osram*, 500 W). Bromine (5.20 mL, 101 mmol, 1.0 eq.) was added over a period of 15 min. The reaction mixture was stirred at 50 °C for 1 h under illumination. Reaction mixture was washed with NaHCO_3 (*aq. sat.*, 3×20 mL) and NaCl (*aq. sat.*, 2×20 mL), dried over MgSO_4 and the solvent was removed *in vacuo*. The desired product was obtained as a pale yellow liquid (26.1 g, 98.9 mmol, 98%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 7.41 - 7.38$ (*m*, 2 H, $2 \times \text{Aryl-H}$), $7.25 - 7.22$ (*m*, 2 H, $2 \times \text{Aryl-H}$), 5.07 (*q*, $J = 6.9$ Hz, 1 H, CHBr), 1.94 (*d*, $J = 6.9$ Hz, 3 H, CH_3).

The spectroscopic data are in accordance with those reported in the literature.^[1]

1-[1-(4-Bromophenyl)ethoxy]-2,2,6,6-tetramethylpiperidine (27)




According to a procedure of *Matyjaszewski et al.*, bromide **26** (25.9 g, 98.3 mmol, 1.0 eq.), TEMPO (18.4 g, 118 mmol, 1.20 eq.), copper powder (6.56 g, 103 mmol, 1.05 eq.), $\text{Cu}(\text{OTf})_2$ (0.36 g, 0.98 mmol, 0.01 eq.) and 4,4-di-*tert*-butyl-2,2-dipyridyl (1.05 g, 3.93 mmol, 0.04 eq.) were added to benzene (190 mL) and warmed to 75 °C for 16 h.^[2] The reaction mixture was filtered through a plug of silica gel with CH_2Cl_2 as solvent. The solvent was removed *in vacuo* and the crude product was purified by FC (pentane/MTBE 20:1). Alkoxyamine **27** as obtained as a colorless solid (28.5 g, 83.8 mmol, 85%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 7.44 - 7.41$ (*m*, 2 H, $2 \times \text{Aryl-H}$), $7.20 - 7.18$ (*m*, 2 H, $2 \times \text{Aryl-H}$), 4.74 (*q*, $J = 6.8$ Hz, 1 H, CHO), $1.59 - 1.37$ (*m*, 9 H, $3 \times \text{CH}_2$, CH_3CH), 1.27 (*s*, 3 H, CH_3), 1.15 (*s*, 3 H, CH_3), 1.02 (*s*, 3 H, CH_3), 0.65 (*s*, 3 H, CH_3).

The spectroscopic data are in accordance with those reported in the literature.^[3]

4-[1-(2,2,6,6-Tetramethylpiperidine-1-yloxy)-ethyl]-benzoic acid (**5**)




Alkoxyamine **27** (14.2 g, 41.8 mmol, 1.0 eq.) was dissolved in THF (170 mL) and *t*-BuLi (1.5 M in pentane, 55.7 mL, 83.6 mmol, 2.0 eq.) was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C for 20 min and CO₂, dried by passing through conc. H₂SO₄, was passed through the reaction mixture over a period of 30 min at -78 °C. The mixture was warmed to rt and HCl (*aq.*, 1 M) was added until the mixture was acidic. The phases were separated and the aqueous layer was extracted with CH₂Cl₂ (2 × 60 mL). The combined organic layers were dried over MgSO₄ and the solvent was removed under reduced pressure. Purification was carried out by crystallization in EtOAc at -18 °C and delivered acid **5** as a colorless solid (12.8 g, 41.8 mmol, 100%).

¹H-NMR (300 MHz, CD₃OD): δ = 8.11 (*d*, *J* = 8.4 Hz, 2 H, 2 × Aryl-*H*), 7.62 (*d*, *J* = 8.3 Hz, 2 H, 2 × Aryl-*H*), 5.68 (*q*, *J* = 6.4 Hz, 1 H, CHO), 2.12 - 1.81 (*m*, 6 H, 3 × CH₂), 1.77 (*d*, *J* = 6.4 Hz, 3 H, CHCH₃), 1.74 (*s*, 3 H, CH₃), 1.55 (*s*, 3 H, CH₃), 1.36 (*s*, 3 H, CH₃), 1.03 (*s*, 3 H, CH₃).

The spectroscopic data are in accordance with those reported in the literature.^[4]

Boc-Lys(Cbz)-Gly-OMe (**28**)




Boc-Lys(Cbz)-Gly-OH (9.51 g, 25.0 mmol, 1.0 eq.) and glycinmethylester hydrochloride (3.46 g, 27.5 mmol, 1.1 eq.) were dissolved in CH₂Cl₂ (120 mL). EDCI (5.75 g, 30.0 mmol, 1.2 eq.), HOBt (4.60 g, 30.0 mmol, 1.2 eq.) and NMM (6.40 mL, 57.5 mmol, 2.3 eq.) were added and the mixture was stirred at rt for 5 h. HCl (*aq.*, 1 M, 20 mL) was added; the phases were separated and the aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL). The combined organic layers were washed with NaOH (*aq.*, 0.25 M, 40 mL) and NaCl (*aq. sat.*, 30 mL) and the

solvent was removed *in vacuo*. Dipeptide **28** was obtained as a colorless solid (10.5 g, 23.3 mmol, 93%).

Mp.: 85 °C. IR (neat): 3318*w*, 2938*w*, 2362*w*, 1667*s*, 1520*s*, 1454*m*, 1367*m*, 1245*s*, 1211*s*, 1165*s*, 1020*m*, 913*w*, 857*w*, 731*m*, 698*m*, 645*m*. ¹H-NMR (300 MHz, CDCl₃): δ = 7.35 - 7.29 (*m*, 5 H, 5 × Aryl-*H*), 6.78 (*br s*, 1 H, CHCONHCH₂), 5.24 - 5.22 (*m*, 1 H, CHCO), 5.08 (*s*, 2 H, CH₂O), 5.05 - 5.00 (*m*, 1 H, CH₂NHCO₂), 4.13 (*br s*, 1 H, NHCO₂), 4.09 - 3.92 (*m*, 2 H, NHCH₂CO₂), 3.70 (*s*, 3 H, OCH₃), 3.22 - 3.15 (*m*, 2 H, CH₂N), 1.90 - 1.78 (*m*, 1 H, CHHCH), 1.70 - 1.61 (*m*, 1 H, CHHCH), 1.56 - 1.47 (*m*, 2 H, CH₂CH₂N), 1.45 - 1.36 (*m*, 11 H, CH₂CH₂CH, 3 × CH₃). ¹³C-NMR (75 MHz, CDCl₃): δ = 172.6 (C), 170.3 (C), 156.7 (C), 155.9 (C), 136.8 (C), 128.6 (2 × CH), 128.2 (3 × CH), 80.3 (C), 66.8 (CH₂), 54.3 (CH), 52.4 (CH₃), 41.2 (CH₂), 40.5 (CH₂), 32.0 (CH₂), 29.6 (CH₂), 28.4 (3 × CH₃), 22.5 (CH₂). MS (ESI): 452 [M+H]⁺, 474 [M+Na]⁺, 925 [2M+H]⁺. HRMS (ESI): calculated for C₂₂H₃₃N₃O₇Na⁺: 474.2211, found: 474.2208. Anal. calculated for C₂₂H₃₃N₃O₇: C: 58.52, H: 7.37, N: 9.31, found: C: 58.54, H: 7.38, N: 9.21.

Boc-Lys(H×HCl)-Gly-OMe (7)




Dipeptide **28** (10.5 g, 23.2 mmol, 1.0 eq.) was dissolved in MeOH (200 mL). Pd/C (10% Pd, 1.24 g, 1.16 mmol, 0.05 eq.) and HCl (1.25 M in MeOH, 3.7 mL, 4.7 mmol, 0.2 eq.) were added and the flask was purged with hydrogen gas. The mixture was stirred for 16 h at rt under atmospheric pressure (balloon). HCl (1.25 M in MeOH, 14.8 mL, 18.6 mmol, 0.8 eq.) was added. The reaction mixture was filtered and the solvent was evaporated *in vacuo*. The desired product was obtained as a colorless solid (8.19 g, 23.2 mmol, 100%).

Mp.: 62 °C. IR (neat): 3296*br m*, 3063*m*, 2936*m*, 1655*s*, 1520*s*, 1367*m*, 1225*m*, 1163*s*, 1086*m*, 1047*m*, 859*w*, 653*m*, 561*m*. ¹H-NMR (300 MHz, CD₃OD): δ = 4.11 - 4.06 (*m*, 1 H, CHCO), 4.06 - 3.89 (*m*, 2 H, CH₂NH₂), 3.73 (*s*, 3 H, OCH₃), 2.96 - 2.91 (*m*, 2 H, CH₂CO₂), 1.90 - 1.79 (*m*, 1 H, CHCHH), 1.74 - 1.62 (*m*, 3 H, CHCHH, CH₂CH₂N), 1.56 - 1.46 (*m*, 11 H, CH₂CH₂CH, 3 × CH₃). ¹³C-NMR (75 MHz, CD₃OD): δ = 175.5 (C), 171.7 (C), 157.8 (C), 80.7 (C), 55.7 (CH), 52.6 (CH₃), 41.8 (CH₂), 40.6 (CH₂), 32.7 (CH₂), 28.7 (3 × CH₃),

28.3 (CH₂), 23.6 (CH₂). MS (ESI): 318 [M+H]⁺, 340 [M+Na]⁺, 635 [2M+H]⁺, 657 [2M+Na]⁺.
HRMS (ESI): calculated for C₁₄H₂₇N₃O₅H⁺: 318.2023, found: 318.2018.

Boc-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl]-benzamide)-Gly-OMe (1)




Dipeptide **7** (10.2 g, 28.9 mmol, 1.0 eq.), alkoxyamine **5** (9.70 g, 31.8 mmol, 1.1 eq.), EDCI (6.64 g, 34.7 mmol, 1.2 eq.), HOBt (5.31 g, 34.7 mmol, 1.2 eq.) and NMM (7.00 mL, 63.5 mmol, 2.2 eq.) were dissolved in CH₂Cl₂ (150 mL) and the reaction mixture was stirred for 16 h at rt. HCl (1 M *aq.*, 100 mL) was added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (4 × 50 mL). The combined organic layers were washed with NaOH (*aq.*, 0.25 M, 50 mL) and NaCl (*aq. sat.*, 50 mL) and dried over MgSO₄. The solvent was removed *in vacuo*. The

crude product was purified by FC (CH₂Cl₂/acetone 5:1) and the desired product was obtained as a colorless solid (13.9 g, 23.0 mmol, 80%).

Mp.: 82 °C. IR (neat): 3315*br m*, 2931*m*, 1641*s*, 1538*s*, 1454*m*, 1366*m*, 1303*m*, 1245*m*, 1171*s*, 1062*w*, 1018*w*, 935*w*, 854*w*, 771*w*, 707*w*. ¹H-NMR (300 MHz, CDCl₃): δ = 7.73 (*d*, *J* = 7.9 Hz, 2 H, 2 × Aryl-*H*), 7.35 (*d*, *J* = 7.7 Hz, 2 H, 2 × Aryl-*H*), 6.84 (*br s*, 1 H, CHCONHCH₂), 6.43 (*br s*, 1 H, CONHCH₂), 5.29 - 5.27 (*m*, 1 H, CHCO), 4.81 (*q*, *J* = 6.7 Hz, 1 H, CHCH₃), 4.15 (*br s*, 1 H, NHCO₂), 4.02 (*t*, *J* = 5.1 Hz, 2 H, NHCH₂CO₂), 3.71 (*s*, 3 H, OCH₃), 3.53 - 3.39 (*m*, 2 H, CH₂CH₂N), 1.98 - 1.85 (*m*, 1 H, CHCHH), 1.80 - 1.60 (*m*, 5 H, CHCHH, CH₂CH₂N, CH₂CH₂C), 1.51 - 1.42 (*m*, 18 H, CH₂CH₂CH, 2 × CH₂C, CH₃CH, C(CH₃)₃), 1.28 (*s*, 3 H, CH₃), 1.16 (*s*, 3 H, CH₃), 1.01 (*s*, 3 H, CH₃), 0.63 (*s*, 3 H, CH₃). ¹³C-NMR (75 MHz, CDCl₃): δ = 172.9 (C), 170.2 (C), 167.8 (C), 155.9 (C), 149.5 (C), 133.1 (C), 127.0 (2 × CH), 126.6, (2 × CH), 83.0 (CH), 60.4 (C), 59.7 (2 × C), 52.3 (CH, CH₃), 41.2 (CH₂), 40.5 (CH₂), 39.3 (2 × CH₂), 32.0 (CH₂), 29.1 (CH₂), 28.4 (3 × CH₃), 23.7 (2 × CH₃), 22.5 (CH₂), 21.1 (CH₃), 20.4 (CH₃), 17.3 (CH₂), 14.2 (CH₃). MS (ESI): 314 [M+H+Na]²⁺, 605 [M+H]⁺, 627 [M+Na]⁺, 1231 [2M+Na]⁺. HRMS (ESI): calculated for C₃₂H₅₂N₄O₇H⁺: 605.3909, found: 605.3904. Anal. calculated. for C₃₂H₅₂N₄O₇×H₂O: C: 61.74, H: 8.74, N: 9.00, found: C: 61.78, H: 8.58, N: 9.00.


Boc-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl]-benzamide)-Gly-OH (8b)



NaOH (*aq.*, 0.25 M, 65 mL) was added to a solution of dipeptide **1** (4.00 g, 6.62 mmol, 1.0 eq.) in MeOH (110 mL). The reaction mixture was stirred for 16 h at rt. CH₂Cl₂ (50 mL) and HCl (*aq.*, 1 M, 30 mL) were added, the phases were separated and the organic layer was extracted with CH₂Cl₂ (4 × 30 mL). The combined organic layers were dried over MgSO₄ and the solvent was evaporated *in vacuo*. Acid **8b** was obtained as a colorless solid (3.85 g, 6.52 mmol, 98%).

Mp.: 126 °C. IR (neat): 3301 br w, 2936 w , 1705 s , 1643 s , 1542 s , 1504 s , 1438 m , 1367 m , 1361 w , 1306 m , 1248 m , 1168 s , 1120 w , 1051 m , 972 w , 912 s , 854 m , 772 w , 728 s , 645 m . ¹H-NMR (300 MHz, CD₃OD): δ = 7.90 (*d*, *J* = 8.8 Hz, 2 H, 2 × Aryl-*H*), 7.59 (*d*, *J* = 8.4 Hz, 2 H, 2 × Aryl-*H*), 5.72 (*q*, *J* = 6.8 Hz, 1 H, CHCH₃), 4.12 - 4.06 (*m*, 1 H, CHCO), 3.93 (*q*, *J* = 17.8 Hz, 2 H, NHCH₂CO), 3.41 (*t*, *J* = 7.1 Hz, 2 H, CH₂NHCO), 2.14 - 1.61 (*m*, 16 H, CHCH₂, NCH₂CH₂, 2 × CCH₂, CH₂CH₂C, CHCH₃, CH₃), 1.53 (*s*, 3 H, CH₃), 1.51 - 1.46 (*m*, 2 H, CH₂CH₂CH₂N), 1.45 (*s*, 9 H, C(CH₃)₃), 1.33 (*s*, 3 H, CH₃), 1.03 (*s*, 3 H, CH₃). ¹³C-NMR (75 MHz, CDCl₃): δ = 173.3 (C), 171.5 (2 × C), 167.0 (C), 144.2 (C), 134.7 (C), 127.9 (2 × CH), 127.1 (2 × CH), 85.1 (CH), 80.1 (C), 70.6 (C), 70.0 (C), 54.4 (CH), 41.4 (2 × CH₂), 39.5 (2 × CH₂), 37.2 (CH₂), 37.0 (CH₂), 29.0 (CH₃), 28.8 (CH₂), 28.4 (3 × CH₃), 23.5 (CH₃), 22.5 (CH₂), 21.2 (CH₃), 21.0 (CH₃), 15.8 (CH₃). MS (ESI): 307 [M+H+Na]²⁺, 591 [M+H]⁺, 613 [M+Na]⁺, 1203 [2M+Na]⁺. HRMS: calculated for C₃₁H₅₀N₄O₇H⁺: 591.3752, found: 591.3754.


**HCl·H-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl]-benzamide)-Gly-OMe
(8a)**



Dipeptide **1** (1.31 g, 2.17 mmol, 1.0 eq.) was added to a methanolic solution of HCl (1.25 M in MeOH, 8 mL) and the mixture was stirred for 16 h at rt. The solvent was removed *in vacuo* and the desired product was obtained as a colorless solid (1.18 g, 2.17 mmol, 100%).

Mp.: 86 °C. IR (neat): 3385*m br*, 3259*m br*, 2945*s*, 2362*w*, 1744*m*, 1686*m*, 1638*s*, 1548*s*, 1439*m*, 1384*w*, 1308*w*, 1210*m*, 940*w*, 856*w*. ¹H-NMR (300 MHz, CD₃OD): δ = 7.93 (*d*, *J* = 8.2 Hz, 2 H, 2 × Aryl-*H*), 7.63 (*d*, *J* = 8.2 Hz, 2 H, 2 × Aryl-*H*), 5.88 (*q*, *J* = 6.5 Hz, 1 H, CHCH₃), 4.13 - 3.93 (*m*, 3 H, CHCO, NHCH₂CO), 3.73 (*s*, 3 H, OCH₃), 3.45 (*t*, *J* = 6.9 Hz, 2 H, CH₂CH₂N), 2.26 - 1.87 (*m*, 6 H, CHCH₂, CH₂CH₂N, CH₂CH₂C), 1.81 - 1.65 (*m*, 10 H, 2 × CH₂C, CH₃, CH₃CH), 1.63 - 1.56 (*m*, 5 H, CH₂CH₂CH, CH₃), 1.36 (*s*, 3 H, CH₃), 1.08 (*s*, 3 H, CH₃). ¹³C-NMR (75 MHz, CD₃OD): δ = 172.4 (C), 170.7 (C), 169.5 (C), 145.4 (C), 136.1 (C), 128.9 (2 × CH), 128.0 (2 × CH), 87.3 (CH), 72.8 (C), 72.2 (C), 54.3 (CH), 52.7 (CH₃), 41.8 (CH₂), 40.4 (CH₂), 38.2 (CH₂), 38.1 (CH₂), 32.2 (CH₂), 30.0 (CH₂), 29.5 (CH₃), 29.3 (CH₃), 23.9 (CH₃), 23.0 (CH₂), 21.0 (CH₃), 20.8 (CH₃), 16.4 (CH₂). MS (ESI): 253 [M+2H]²⁺, 505 [M+H]⁺, 527 [M+Na]⁺, 1009 [2M+H]⁺, 1031 [2M+Na]⁺. HRMS (ESI): calculated for C₂₇H₄₄N₄O₅Na⁺: 527.3204, found: 527.3204.

**Boc-bis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-OMe
(9)**




Acid **8b** (3.48 g, 5.90 mmol, 1.0 eq.) and amine hydrochloride **8a** (3.20 g, 5.90 mmol, 1.0 eq.) were dissolved in CH₂Cl₂ (60 mL). EDCI (1.36 g, 7.10 mmol, 1.2 eq.), HOBt (1.09 g, 7.10 mmol, 1.2 eq.) and NMM (1.4 mL, 13 mmol, 2.2 eq.) were added and the reaction mixture was stirred for 16 h at rt. HCl (*aq.*, 1 M, 30 mL) was added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were washed with NaOH (*aq.*, 0.25 M, 40 mL) and NaCl (*aq. sat.*, 30 mL) and dried over MgSO₄.

The solvent was removed under reduced pressure and the crude product was purified by FC (CH₂Cl₂/acetone 3:1 → 1:1). Tetrapeptide **9** was obtained as a colorless solid (4.91 g, 4.56 mmol, 77%).

Mp.: 144 °C. IR (neat): 3297*br m*, 2933*m*, 1749*w*, 1632*s*, 1535*s*, 1455*w*, 1364*m*, 1254*m*, 1179*m*, 1063*m*, 1018*w*, 908*m*, 853*w*, 730*s*. ¹H-NMR (300 MHz, CDCl₃): δ = 7.78 - 7.74 (*m*, 4 H, 4 × Aryl-*H*), 7.62 (*br s*, 1 H, CH₂CONH), 7.56 - 7.52 (*m*, 1 H, NHCH₂CO₂), 7.44 (*br s*, 1 H, NHCH₂CO), 7.32 (*d*, *J* = 8.0 Hz, 4 H, 4 × Aryl-*H*), 6.96 (*br s*, 2 H, 2 × CH₂NHCO), 5.89 (*br s*, 1 H, CO₂NH), 4.79 (*q*, *J* = 6.4 Hz, 2 H, 2 × CHCH₃), 4.64 - 4.57 (*m*, 1 H, CH₂CONHCH), 4.27 - 4.18 (*m*, 1 H, CO₂NHCH), 4.12 - 3.87 (*m*, 4 H, 2 × NHCH₂CO), 3.65 (*s*, 3 H, OCH₃), 3.51 - 3.32 (*m*, 4 H, 2 × CH₂NHCOC), 2.00 - 1.33 (*m*, 39 H, 2 × CHCH₂, 2 × CHCH₂CH₂, 2 × NHCH₂CH₂, C(CH₃)₃, 2 × CHCH₃, 4 × CH₂C, 2 × CH₂CH₂C), 1.27 (*s*, 6 H, 2 × CH₃), 1.15 (*s*, 6 H, 2 × CH₃), 1.00 (*s*, 6 H, 2 × CH₃), 0.62 (*s*, 6 H, 2 × CH₃). ¹³C-NMR (75 MHz, CDCl₃): δ = 173.6 (C), 172.5 (C), 170.2 (C), 169.4 (C), 168.0 (2 × C), 156.3 (C), 149.5 (C), 149.4 (C), 133.1 (C), 133.0 (C), 127.2 (4 × CH), 126.6 (4 × CH), 83.0 (2 × CH), 80.0 (C), 59.9 (4 × C), 57.8 (CH), 53.2 (CH), 52.3 (CH₃), 43.5 (CH₂), 41.2 (CH₂), 40.4 (4 × CH₂), 39.8 (CH₂), 39.7 (CH₂), 34.4 (4 × CH₃), 32.4 (CH₂), 32.1 (CH₂), 29.4 (CH₂), 29.2 (CH₂), 29.4 (3 × CH₃), 23.7 (2 × CH₃), 22.9 (2 × CH₂), 20.4 (4 × CH₃), 17.3 (2 × CH₂). MS (ESI): 539 [M+2H]²⁺, 550 [M+H+Na]²⁺, 1078 [M+H]⁺, 1100 [M+Na]⁺. HRMS (ESI):

calculated for $C_{58}H_{92}N_8O_{11}NaH^{2+}$: 550.3425, found: 550.3416. Anal. calculated for $C_{58}H_{92}N_8O_{11}$: C: 64.66, H: 8.61, N: 10.40, found: C: 64.34, H: 8.67, N: 10.30.


**Boc-bis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl]-benzamide)-Gly]-OH
(10b)**



NaOH (0.25 M *aq.*, 50 mL) was added to a solution of tetrapeptide **9** (1.70 g, 1.57 mmol, 1.0 eq.) in MeOH (80 mL). The reaction mixture was stirred for 16 h at rt. CH_2Cl_2 (50 mL) and HCl (*aq.*, 1 M, 50 mL) were added and the phases were separated. The aqueous layer was extracted with CH_2Cl_2 (4 × 50 mL). The combined organic layers were dried over $MgSO_4$ and the solvent was removed *in vacuo*. The product was obtained as a colorless solid (1.47 g, 1.38 mmol, 88%).

Mp.: 172 °C. IR (neat): 3288 br *m*, 2929 m , 2364 w , 1646 s , 1541 s , 1440 m , 1384 m , 1306 m , 1247 m , 1169 s , 1052 w , 938 w , 855 w , 733 s . 1H -NMR (300 MHz, CD_3OD): δ = 7.93 (*d*, J = 7.6 Hz, 4 H, 4 × Aryl-*H*), 7.62 (*d*, J = 8.3 Hz, 4 × Aryl-*H*), 5.75 (*q*, J = 6.2 Hz, 2 H, 2 × $CHCH_3$), 4.44 (*dd*, J_1 = 5.1 Hz, J_2 = 8.7 Hz, 1 H, $CHCO$), 4.04 (*dd*, J_1 = 5.4 Hz, J_2 = 8.5 Hz, 1 H, $CHCO$), 3.98 - 3.84 (*m*, 4 H, 2 × $NHCH_2CO$), 3.45 - 3.40 (*m*, 4 H, 2 × CH_2NCO), 2.17 - 1.64 (*m*, 42 H, 2 × $CHCH_2$, 2 × $CHCH_2CH_2$, 2 × $NHCH_2CH_2$, 4 × CCH_2 , 2 × CCH_2CH_2 , 2 × $CHCH_3$, 4 × CCH_3), 1.47 (*s*, 9 H, $C(CH_3)_3$), 1.37 (*s*, 6 H, 2 × CCH_3), 1.06 (*s*, 6 H, 2 × CCH_3). ^{13}C -NMR (75 MHz, CD_3OD): δ = 176.0 (C), 174.5 (C), 172.6 (C), 171.6 (C), 169.4 (2 × C), 158.1 (C), 145.5 (2 × C), 136.1 (2 × C), 128.9 (4 × CH), 128.0 (4 × CH), 87.4 (2 × CH), 80.7 (C), 56.4 (4 × C), 54.6 (2 × CH), 43.7 (CH_2), 41.8 (CH_2), 40.6 (CH_2), 40.7 (CH_2), 38.5 (2 × CH_2), 38.4 (2 × CH_2), 32.6 (2 × CH_2), 30.1 (2 × CH_2), 29.9 (2 × CH_3), 29.7 (2 × CH_3), 28.8 (3 × CH_3), 24.2 (2 × CH_2), 23.9 (2 × CH_3), 20.9 (2 × CH_3), 20.8 (2 × CH_3), 16.6 (2 × CH_2). MS (ESI): 532 $[M+2H]^{2+}$, 1064 $[M+H]^+$, 1086 $[M+Na]^+$. HRMS (ESI): calculated for $C_{57}H_{90}N_8O_{11}H^+$: 1063.6802, found: 1063.6810.


**Boc-tetrakis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-
OMe (11)**



Acid **10b** (190 mg, 179 μmol , 1.0 eq.) and amine hydrochloride **10a** (181 mg, 179 μmol , 1.0 eq.) were dissolved in DMF (2 mL). EDCI (51.0 mg, 269 μmol , 1.5 eq.), HOBt (33.0 mg, 215 μmol , 1.2 eq.) and NMM (49.0 μL , 448 μmol , 2.5 eq.) were added and the reaction mixture was stirred for 16 h at rt. The solvent was removed *in vacuo* and the crude product was purified by RP-FC ($\text{H}_2\text{O} \rightarrow \text{H}_2\text{O}/\text{MeOH}$ 1:1 \rightarrow MeOH). Octapeptide **11** was obtained as a colorless solid (255 mg, 126 μmol , 70%).

Mp.: Decomp. above 240 $^\circ\text{C}$. IR (neat): 3298 br m , 2930 m , 2264 w , 2003 w , 1654 s , 1541 s , 1377 w , 1305 w , 1181 w , 856 w , 771 w . MS (ESI): 682 $[\text{M}+2\text{H}+\text{Na}]^{3+}$, 690 $[\text{M}+\text{H}+2\text{Na}]^{3+}$, 1012 $[\text{M}+2\text{H}]^{2+}$, 1023 $[\text{M}+\text{H}+\text{Na}]^{2+}$, 1034 $[\text{M}+2\text{Na}]^{2+}$, 2023 $[\text{M}+\text{H}]^+$, 2045 $[\text{M}+\text{Na}]^+$. HRMS (ESI): calculated for $\text{C}_{110}\text{H}_{172}\text{N}_{16}\text{O}_{19}\text{NHNa}^{2+}$: 1022.6475, found: 1022.6427. Due to low solubility of **11** in common solvents we did not obtain NMR-Spectra.

**Boc-tetrakis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-
OH (12b)**




Octapeptide **11** (100 mg, 50.0 μmol , 1.0 eq.) was dissolved in MeOH (300 mL) in an ultrasonic bath. NaOH (*aq.*, 1 M, 20 mL) was added and the reaction mixture was stirred for 40 h at rt. Formic acid (2.5 mL) was added and the volatile components were removed *in vacuo*. The crude product was purified by RP-FC (H_2O (200 mL) \rightarrow MeOH). The desired product was obtained as a colorless solid (91 mg, 45 μmol , 91%).

Mp.: Decomp. above 200 °C. IR (neat): 3288 $br m$, 2929 m , 1654 s , 1539 s , 1454 m , 1385 m , 1304 m , 1256 m , 1179 w , 1133 w , 1094 m , 1063 m , 1019 w , 935 w , 854 w , 770 w , 661 m . MS (ESI): 670 [M+3H]³⁺, 677 [M+2H+Na]³⁺, 685 [M+H+2Na]³⁺, 692 [M+3Na]³⁺, 1005 [M+2H]²⁺, 1016 [M+H+Na]²⁺, 1027 [M+2Na]²⁺, 2009 [M+H]⁺, 2031 [M+Na]⁺. HRMS (ESI): calculated for C₁₀₉H₁₇₀N₁₆O₁₉HNa²⁺: 1015.6397, found: 1015.6398.

Due to low solubility of **12b** in common solvents we did not obtain NMR-Spectra.


HCl·H-Tetrakis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-OMe (**12a**)



Octapeptide **11** (100 mg, 0.050 mmol, 1.0 eq.) was suspended in MeOH (5 mL) and a methanolic solution of HCl (1.25 M in MeOH, 0.50 mL, 0.63 mmol, 12.5 eq.) was added. The reaction mixture was stirred for 48 h at rt. The solvent was removed *in vacuo* and amine hydrochloride **12a** was obtained as a colorless solid (97 mg, 50 μmol, 100%).

Mp.: Decomp. above 200 °C. IR (Film): 3302 $br m$, 2935 m , 1656 s , 1452 s , 1439 m , 1385 m , 1306 w , 1093 w , 938 w , 855 w , 590 w . MS (ESI): 641 [M+3H]³⁺, 962 [M+2H]²⁺, 973 [M+H+Na]²⁺, 984 [M+2Na]²⁺, 1923 [M+H]⁺, 1945 [M+Na]⁺. HRMS (ESI): calculated for C₁₀₅H₁₆₄N₁₆O₁₇HNa²⁺: 972.6213, found: 972.6243. Due to low solubility of **12a** in common solvents we did not obtain NMR-Spectra.


**Boc-hexakis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-
OMe (13)**



Acid **12b** (100 mg, 50.0 μmol , 1.0 eq.) and amine hydrochloride **10a** (50.0 mg, 50.0 μmol , 1.0 eq.) were dissolved in DMF (3 mL). HATU (29 mg, 75 μmol , 1.5 eq.), HOAt (10 mg, 75 μmol , 1.5 eq.) and DIPEA (44.0 μL , 250 μmol , 5.0 eq.) were added and the reaction mixture was stirred for 16 h at rt. MeOH (10 mL) and acetone (10 mL) were added and the product was crystallized overnight at 4 $^{\circ}\text{C}$. The crystallization process was repeated once. Dodecanptide **13** was obtained as a colorless solid (111 mg, 37.4 μmol , 75%).

Mp.: Decomp. above 240 $^{\circ}\text{C}$. IR (neat): 3285 $br\ w$, 2931 w , 1627 s , 1525 s , 1439 m , 1361 m , 1301 m , 1210 m , 1181 m , 1062 s , 1017 m , 935 m , 852 m , 707 m . HRMS (ESI): calculated for $\text{C}_{162}\text{H}_{252}\text{N}_{24}\text{O}_{27}$: 2965.90783, found: 2965.91262, calculated from: 495.49288 $[\text{M}+6\text{H}]^{6+}$, 594.18985 $[\text{M}+5\text{H}]^{5+}$, 742.73611 $[\text{M}+4\text{H}]^{4+}$, 989.97935 $[\text{M}+3\text{H}]^{3+}$, 1484.96729 $[\text{M}+2\text{H}]^{2+}$. Due to low solubility of **13** in common solvents we did not obtain NMR-Spectra.


**Boc-octakis[-Lys(4-[1-{2,2,6,6-tetramethylpiperidine-1-yloxy}-ethyl)-benzamide)-Gly]-
OMe (14)**



Acid **12b** (73 mg, 36 μmol , 1.0 eq.) and amine hydrochloride **12a** (71 mg, 36 μmol , 1.0 eq.) were dissolved in *N*-methylpyrrolidone (5 mL). HATU (21 mg, 54 μmol , 1.5 eq.), HOAt (7.4 mg, 54 μmol , 1.5 eq.) and DIPEA (32 μL , 0.18 mmol, 5.0 eq.) were added and the reaction mixture was stirred for 16 h at rt. MeOH (20 mL) was added and the product was crystallized at 4 $^{\circ}\text{C}$. The crystallization process was repeated once and the product was obtained as a colorless solid (88 mg, 22 μmol , 62%).

Mp.: Decomp. above 260 °C. IR (neat): 3286 $br w$, 2931 w , 1626 s , 1522 s , 1439 m , 1361 m , 1302 m , 1210 m , 1133 m , 1062 s , 1018 m , 935 m , 852 m , 653 m . HRMS (ESI): calculated for C₂₁H₃₃N₃O₃: 3910.51774, found: 3910.51731, calculated from: 559.93891 [M+7H]⁷⁺, 653.09434 [M+6H]⁶⁺, 783.51189 [M+5H]⁵⁺. Due to low solubility of **14** in common solvents we did not obtain NMR-Spectra.


3-Nitropentane (29)

 Sodium nitrite (44.2 g, 640 mmol, 1.6 eq.) was added to a solution of 3-bromopentane (50.0 mL, 400 mmol, 1.0 eq.) in DMSO (350 mL). The reaction mixture was stirred for 18 h at rt, cooled to 0 °C and water was added until the formed precipitate was dissolved. The mixture was extracted with pentane (3 × 60 mL). The combined extracts were washed with water (2 × 10 mL), dried over MgSO₄ and the solvent was removed *in vacuo*. The product was obtained as a pale blue liquid and used without further purification (29.8 g, 254 mmol, 64%).

¹H-NMR (300 MHz, CDCl₃): δ = 4.36 - 4.27 (*m*, 1 H, CH), 1.99 - 1.91 (*m*, 2 H, CH₂), 1.82 - 1.75 (*m*, 2 H, CH₂), 0.95 (*t*, *J* = 7.4 Hz, 6 H, 2 × CH₃).

The spectroscopic data are in accordance with those reported in the literature.^[5]


N-*tert*-Butyl-(2-ethyl-2-nitrobutyl)-amine (30)

 Formaldehyde (37% wt. in H₂O, 6.7 mL, 89 mmol, 1.0 eq.) was added slowly to *tert*-butylamine at 0 °C (9.5 mL, 89 mmol, 1.0 eq.). 3-Nitropentane (10.4 g, 89.0 mmol, 1.0 eq.) was added and the reaction mixture was stirred for 18 h at rt. Na₂SO₄ was added until a phase separation occurred. The aqueous layer was removed and the organic layer was stirred for additional 5 d at rt. The mixture was dried over Na₂SO₄ and the crude product was purified by distillation (86 °C, 5.3 mbar). Amine **30** was obtained as a colorless liquid (14.1 g, 69.6 mmol, 78%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 2.93$ (*s*, 2 H, CH_2NH), 1.97 (*q*, $J = 7.6$ Hz, 4 H, $2 \times \text{CH}_2$), 1.05 (*s*, 9 H, $\text{C}(\text{CH}_3)_3$), 0.85 (*t*, $J = 7.5$ Hz, 6 H, $2 \times \text{CH}_3$).

The spectroscopic data are in accordance with those reported in the literature.^[5]

***N*-tert-Butyl-2-ethylbutan-1,2-diamine (31)**




Amine **30** (14.0 g, 69.0 mmol, 1.0 eq.) was dissolved in a mixture of HOAc (100 mL) and H_2O (150 mL). While cooling in an ice bath, zinc powder (27.1 g, 414 mmol, 6.0 eq.) was added and the reaction mixture was stirred at rt for 2 h. The excess of zinc was filtered off and solid NaOH was added to the filtrate until the solution turned basic. The mixture was extracted with Et_2O (3×200 mL) and the extracts were dried over MgSO_4 . The solvent was evaporated *in vacuo* and the product was obtained as a colorless liquid (10.9 g, 63.3 mmol, 92%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 2.36$ (*s*, 2 H, CH_2N), 1.40 - 1.29 (*m*, 4 H, $2 \times \text{CH}_2$), 1.07 (*s*, 9 H, $\text{C}(\text{CH}_3)_3$), 0.82 (*t*, $J = 7.6$ Hz, 6 H, $2 \times \text{CH}_3$).

The spectroscopic data are in accordance with those reported in the literature.^[5]

1-tert-Butyl-3,3,5,5-tetraethyl-2-piperazinone (32)




KOH (18.5 g, 329 mmol, 5.3 eq.) powder was added slowly at 10 °C to a mixture of diamine **31** (10.7 g, 62.2 mmol, 1.00 eq.), 3-pentanone (99.0 mL, 933 mmol, 15.0 eq.) and CHCl_3 (8.0 mL, 0.1 mol, 1.6 eq.). After stirring for for 18 h at rt, the reaction mixture filtered. The filtrate was evaporated to dryness and the crude product was purified by FC (pentane/MTBE 10:1). Piperazinone **32** was obtained as a pale yellow oil (10.1 g, 37.6 mol, 60%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 3.15$ (*s*, 2 H, CH_2N), 1.58 (*q*, $J = 7.4$ Hz, 4 H, $2 \times \text{CH}_2$), 1.43 - 1.34 (*m*, 4 H, $2 \times \text{CH}_2$), 1.41 (*s*, 9 H, $\text{C}(\text{CH}_3)_3$), 0.86 (*t*, $J = 7.4$ Hz, 6 H, $2 \times \text{CH}_3$), 0.83 (*t*, $J = 7.4$ Hz, 6 H, $2 \times \text{CH}_3$).

The spectroscopic data are in accordance with those reported in the literature.^[5]

1-*tert*-Butyl-3,3,5,5-tetraethylpiperazin-2-one-4-oxyl radical (15)




Piperazinone **32** (2.44 g, 9.08 mmol, 1.0 eq.) was dissolved in EtOAc (20 mL). Peroxyacetic (39% wt. in HOAc, 2.31 mL, 13.6 mmol, 1.5 eq.) acid was added at 0 °C. The reaction mixture was stirred for 16 h at rt. Pentane (60 mL) was added and the mixture was washed with NaHCO_3 (*aq. sat.*, 3×40 mL). The organic layer was dried over MgSO_4 and the solvent was evaporated *in vacuo*. Purification was carried out by FC (pentane/EtOAc 10:1) and delivered nitroxide **15** as red oil (2.47g, 8.71 mmol, 96%).

MS (ESI): 284 $[\text{M}+\text{H}]^+$, 306 $[\text{M}+\text{Na}]^+$, 589 $[\text{2M}+\text{Na}]^+$. HRMS: calculated. for $\text{C}_{16}\text{H}_{31}\text{N}_2\text{O}_2\text{Na}^+$: 306.2278, found: 306.2275.

The spectrometric data are in accordance with those reported in the literature.^[5]

4-[1-(4-Bromophenyl)-ethoxy]-1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one (33)




According to a procedure of *Matyjaszewski et al.*, bromide **26** (2.02 g, 7.66 mmol, 1.0 eq.), nitroxide **15** (2.17 g, 7.66 mmol, 1.0 eq.), copper powder (511 mg, 8.04 mmol, 1.05 eq.), $\text{Cu}(\text{OTf})_2$ (28.0 mg, 80.0 μmol , 0.01 eq.) and 4,4-di-*tert*-butyl-2,2-dipyridyl (80.0 mg, 310 μmol , 0.04 eq.) were suspended in benzene (15 mL) and the mixture was warmed to 75 °C for 16 h. The crude mixture was filtered through a plug of silica with CH_2Cl_2 as eluent. The solvent was evaporated *in vacuo* and the crude product was purified by FC (pentane/MTBE 20:1). Alkoxyamine **33** was isolated as a colorless solid (3.29 g, 7.04 mmol, 92%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): $\delta = 7.44$ (*d*, $J = 8.4$ Hz, 2 H, $2 \times \text{Aryl-H}$), 7.16 (*d*, $J = 8.1$ Hz, 2 H, $2 \times \text{Aryl-H}$), $4.70 - 4.60$ (*m*, 1 H, CHCH_3), $3.21 - 2.95$ (*m*, 2 H, CH_2N), $2.16 - 1.50$ (*m*, 7 H, $2 \times \text{CH}_2$, CHCH_3), $1.44 - 1.38$ (*m*, 13 H, $2 \times \text{CH}_2$, $\text{C}(\text{CH}_3)_3$), $1.08 - 0.93$ (*m*, 6 H, $2 \times \text{CH}_3$), $0.86 - 0.60$ (*m*, 6 H, $2 \times \text{CH}_3$).

The spectrometric data are in accordance with those reported in the literature.^[6]

4-[1-(1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy)-ethyl]-benzoic acid (**34**)




Alkoxyamine **33** (9.50 g, 20.3 mmol, 1.0 eq.) was dissolved in THF (90 mL) and *t*-BuLi (1.5 M in pentane, 27.1 mL, 40.6 mmol, 2.0 eq.) was added slowly at -78 °C. The reaction mixture was stirred at -78 °C for 20 min. CO_2 , dried by passing through conc. H_2SO_4 , was passed through the reaction mixture for 30 min at -78 °C. The mixture was warmed to rt and HCl (*aq.*, 1 M) was added until the mixture turned acidic. The phases were separated and the aqueous layer was extracted with CH_2Cl_2 (2×40 mL). The combined organic layers were dried over MgSO_4 and the solvent was removed *in vacuo*. Purification was carried out by crystallization in EtOAc at -18 °C and afforded the desired product as a colorless solid (7.71 g, 17.8 mmol, 88%).

Mp.: 157 °C. IR (neat): $2973s$, $2668w$, $1691s$, $1641s$, $1456m$, $1420s$, $1366m$, $1283s$, $1205s$, $1063m$, $994w$, $912m$, $858m$, $778w$, $731s$, $645w$. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 8.07 (*d*, $J = 8.3$ Hz, 2 H, $2 \times \text{Aryl-H}$), 7.39 (*d*, $J = 8.6$ Hz, 2 H, $2 \times \text{Aryl-H}$), $4.82 - 4.73$ (*m*, 1 H, CHCH_3), $3.23 - 2.96$ (*m*, 2 H, CH_2N), $2.23 - 1.23$ (*m*, 11 H, $4 \times \text{CH}_2$, CHCH_3), 1.39 (*s*, 9 H, $\text{C}(\text{CH}_3)_3$), $1.10 - 0.95$ (*m*, 6 H, $2 \times \text{CH}_3$), $0.87 - 0.58$ (*m*, 6 H, $2 \times \text{CH}_3$). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): doubled set of resonance obtained, $\delta = 172.9$ (C), 172.8 (C), 171.4 (C), 171.3 (C), 150.6 (C), 150.3 (C), 130.3 ($4 \times \text{CH}$), 128.6 (C), 128.3 (C), 127.1 ($2 \times \text{CH}$), 126.8 ($2 \times \text{CH}$), 82.8 (CH), 82.6 (CH), 73.6 (C), 73.2 (C), 62.8 (C), 62.5 (C), 57.3 ($2 \times \text{C}$), 47.1 (CH_2), 46.1 (CH_2), 34.9 (CH_2), 33.4 (CH_2), 29.4 (CH_2), 29.0 (CH_2), 28.3 ($6 \times \text{CH}_3$), 26.9 (CH_2), 26.7 (CH_2), 24.7 ($2 \times \text{CH}_2$), 23.3 (CH_3), 22.3 (CH_3), 11.8 (CH_3), 11.3 (CH_3), 9.7 (CH_3), 9.4 (CH_3), 9.2 ($2 \times \text{CH}_3$), 8.4 (CH_3), 7.7 (CH_3). MS (ESI): 433 [$\text{M}+\text{H}$] $^+$, 455 [$\text{M}+\text{Na}$] $^+$, 888 [$2\text{M}+\text{Na}$] $^+$, 1320 [$3\text{M}+\text{Na}$] $^+$. HRMS (ESI): calculated for $\text{C}_{25}\text{H}_{10}\text{N}_2\text{O}_4\text{H}^+$: 433.3061, found: 433.3065.

Anal. calculated for C₂₅H₁₀N₂O₄: C: 69.41, H: 9.32, N: 6.48, found: C: 69.13, H: 9.37, N: 6.33.

Boc-Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly-OMe (16)




Acid **34** (9.07 g, 21.0 mmol, 1.1 eq.), amine hydrochloride **7** (6.73 g, 19.1 mmol, 1.0 eq.), EDCI (4.38 g, 22.9 mmol, 1.2 eq.), HOBt (3.50 g, 22.9 mmol, 1.0 eq.) and NMM (4.63 mL, 41.9 mmol, 2.2 eq.) were dissolved in CH₂Cl₂ (100 mL) and the reaction mixture was stirred for 16 h at rt. After addition of HCl (*aq.*, 0.5 M, 60 mL) the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 50 mL). The combined organic layers were washed with NaOH (*aq.*, 0.25 M, 40 mL) and NaCl (*aq. sat.*, 50 mL), dried over MgSO₄ and the solvent was evaporated *in vacuo*. Purification by FC (CH₂Cl₂/acetone 5:1) delivered the desired product as a colorless solid (8.87 g, 12.1 mmol, 63%).

Mp.: 88 °C. IR (neat): 3313 br m , 2973 s , 1642 s , 1538 s , 1455 m , 1366 s , 1305 m , 1205 s , 1170 s , 1062 m , 1018 w , 915 w , 855 m , 735 m , 625 w , 568 w . ¹H-NMR (300 MHz, CDCl₃): 7.75 (d , J = 8.1 Hz, 2 H, 2 × Aryl- H), 7.32 (d , J = 8.0 Hz, 2 H, 2 × Aryl- H), 6.82 (br t , J = 5.3 Hz, 1 H, CHCONH), 6.44 (br s , 1 H, CH₂NHCO), 5.27 - 5.24 (m , 1 H, CHCO), 4.78 - 4.69 (m , 1 H, CHCH₃), 4.19 - 4.10 (m , 1 H, NHCO₂), 4.02 (t , J = 5.2 Hz, 2 H, NHCH₂CO₂), 3.71 (s , 3 H, OCH₃), 3.51 - 3.44 (m , 2 H, CH₂CH₂N), 3.21 - 3.00 (m , 2 H, CH₂N), 1.98 - 1.56 (m , 11 H, CH₂CH₂N, CH₂CH, CHCH₂CH₂, CH₂CH₃, CHCH₃), 1.50 - 1.42 (m , 15 H, 3 × CH₂CH₃, OC(CH₃)₃), 1.37 (s , 9 H, NC(CH₃)₃), 1.09 - 0.94 (m , 6 H, 2 × CH₃), 0.85 - 0.60 (m , 6 H, 2 × CH₃). ¹³C-NMR (75 MHz, CDCl₃): 172.7 (C), 170.2 (C), 167.7 (C), 156.0 (C), 148.0 (C), 133.6 (C), 127.1 (2 × CH), 126.7 (2 × CH), 110.1 (C), 82.7 (CH), 80.3 (C), 73.7 (C), 62.8 (C), 57.3 (C), 54.4 (CH), 52.4 (CH₃), 47.1 (CH₂), 46.2 (CH₂), 41.3 (CH₂), 39.4 (CH₂), 34.8 (CH₂), 33.6 (CH₂), 31.8 (CH₂), 29.2 (CH₂), 28.4 (CH₃), 28.3 (CH₃), 27.0 (CH₂), 24.7 (CH₂), 23.3 (CH₃), 22.6 (CH₃), 11.8 (CH₃), 11.3 (CH₃), 9.7 (CH₃), 9.4 (CH₃), 9.2 (CH₃), 8.4 (CH₃), 7.8 (CH₃). MS (ESI): 754 [M+Na]⁺, 1486 [2M+Na]⁺. HRMS (ESI): calculated for

$C_{39}H_{65}N_5O_8Na^+$: 754.4725, found: 754.4712. Anal. calculated for $C_{39}H_{65}N_5O_8$: C: 63.99, H: 8.95, N: 9.57, found: C: 63.59, H: 9.07, N: 9.34.


Boc-Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly-OH (35)



NaOH (aq., 0.25 M, 50 mL) was added to a solution of dipeptide **16** (3.55 g, 4.85 mmol, 1.0 eq.) in MeOH (80 mL). The reaction mixture was stirred for 18 h at rt. HCl (aq., 1 M, 30 mL) was added and the mixture was extracted with CH_2Cl_2 (4×50 mL). The combined organic layers were dried over $MgSO_4$ and the solvent was removed *in vacuo*. The product was obtained as a colorless solid (3.39 g, 4.72 mmol, 97%).

Mp.: 97 °C. IR (neat): 3320 br w, 2974 m , 2245 w , 1635 s , 1540 s , 1455 m , 1366 m , 1308 m , 1203 m , 1167 s , 1061 w , 1018 w , 910 s , 854 w , 729 s , 646 m . 1H -NMR (300 MHz, $CDCl_3$): δ = 7.77 (d , J = 8.5 Hz, 2 H, 2 \times Aryl- H), 7.39 - 7.35 (m , 2 H, 2 \times Aryl- H), 4.80 - 4.72 (m , 1 H, $CHCH_3$), 4.05 - 4.01 (m , 1 H, $CHCO$), 3.95 - 3.79 (m , 2 H, $NHCH_2CO$), 3.35 (t , J = 6.7 Hz, 2 H, CH_2CH_2N), 3.18 - 3.02 (m , 2 H, CH_2N), 2.15 - 1.53 (m , 11 H, CH_2CH , CH_2CH_2N , $CHCH_2CH_2$, CH_2CH_3 , $CHCH_3$), 1.46 - 1.35 (m , 24 H, 3 \times CH_2CH_3 , $OC(CH_3)_3$, $NC(CH_3)_3$), 1.09 - 0.95 (m , 6 H, 2 \times CH_3), 0.82 - 0.59 (m , 6 H, 2 \times CH_3). ^{13}C -NMR (300 MHz, $CDCl_3$): 173.2 (C), 172.9 (C), 171.9 (C), 168.1 (C), 156.2 (C), 147.8 (C), 133.4 (C), 127.1 (2 \times CH), 126.7 (2 \times CH), 82.6 (CH), 80.2 (C), 73.5 (C), 62.5 (C), 57.3 (C), 54.3 (CH), 47.0 (CH_2), 46.0 (CH_2), 41.3 (CH_2), 39.6 (CH_2), 35.4 (CH_2), 33.6 (CH_2), 32.2 (CH_2), 28.4 (CH_3), 28.3 (CH_3), 26.8 (CH_2), 24.6 (CH_2), 23.3 (CH_3), 22.6 (CH_2), 22.2 (CH_3), 11.8 (CH_3), 11.4 (CH_3), 9.7 (CH_3), 9.4 (CH_3), 9.2 (CH_3), 8.3 (CH_3), 7.7 (CH_3). MS (ESI): 718 $[M+H]^+$, 740 $[M+Na]^+$, 1434 $[2M+H]^+$. HRMS (ESI): calculated for: $C_{38}H_{63}N_5O_8Na^+$: 740.4569, found: 740.4554.

HCl·H-Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly-OMe (36)




Dipeptide **16** (2.5 g, 3.4 mmol, 1.0 eq.) was added to a methanolic solution of HCl (1.25 M in MeOH, 12 mL, 15 mmol, 4.4 eq.) and the mixture was stirred for 16 h at rt. The solvent was removed *in vacuo* and amine hydrochloride was obtained as a colorless solid (2.28 g, 3.40 mmol, 100%).

Mp.: 92 °C. IR (neat): 3329*br s*, 2973*s*, 2363*w*, 1747*m*, 1646*s*, 1547*m*, 1458*s*, 1366*m*, 1309*m*, 1210*s*, 1063*w*, 994*w*, 855*w*, 770*w*.

¹H-NMR (300 MHz, CD₃OD): δ = 7.77 (*d*, *J* = 8.2 Hz, 2 H, 2 × Aryl-*H*), 7.39 - 7.34 (*m*, 2 H, 2 × Aryl-*H*), 4.81 - 4.70 (*m*, 1 H, *CHCH*₃), 4.05 - 3.85 (*m*, 3 H, *CHCO*, *NHCH*₂*CO*), 3.65 (*s*, 3 H, *OCH*₃), 3.37 (*t*, 2 H, *J* = 7.1 Hz, *CH*₂*CH*₂*N*), 3.16 - 3.00 (*m*, 2 H, *CH*₂*N*), 2.11 - 1.34 (*m*, 26 H, *CH*₂*CH*, *CH*₂*CH*₂*N*, *CHCH*₂*CH*₂, 4 × *CH*₂*CH*₃, *CHCH*₃, *C(CH*₃*)*₃), 1.08 - 0.94 (*m*, 6 H, 2 × *CH*₃), 0.80 - 0.73 (*m*, 3 H, *CH*₃), 0.65 - 0.57 (*m*, 3 H, *CH*₃). ¹³C-NMR (75 MHz, CD₃OD): δ = 174.6 (C), 172.5 (C), 171.4 (C), 170.0 (C), 149.1 (C), 135.0 (C), 128.3 (2 × CH), 127.9 (2 × CH), 84.0 (CH), 74.7 (C), 63.6 (C), 58.7 (C), 54.3 (CH), 52.8 (CH₃), 41.8 (CH₂), 40.4 (CH₂), 36.2 (CH₂), 34.9 (CH₂), 32.2 (CH₂), 30.3 (CH₂), 30.1 (CH₂), 28.4 (CH₃), 27.7 (CH₂), 25.8 (CH₂), 23.5 (CH₃), 23.0 (CH₂), 22.3 (CH₃), 12.2 (CH₃), 11.8 (CH₃), 9.9 (CH₃), 8.6 (CH₃), 8.0 (CH₃). MS (ESI): 632 [M+H]⁺, 654 [M+Na]⁺. HRMS (ESI): calculated for C₃₄H₅₇N₅O₆H⁺: 632.4381, found: 632.4382.

Boc-bis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly]-OMe (17)




Acid **35** (2.26 g, 3.14 mmol, 1.0 eq.) and amine hydrochloride **36** (2.10 g, 3.14 mmol, 1.0 eq.) were dissolved in CH₂Cl₂ (40 mL). EDCI (722 mg, 3.77 mmol, 1.2 eq.), HOBt (577 mg, 3.77 mmol, 1.2 eq.) and NMM (0.76 mL, 6.91 mmol, 2.2 eq.) were added and the reaction mixture was stirred for 16 h at rt. HCl (*aq.*, 1 M, 20 mL) was added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were washed with NaOH (*aq.*, 0.25 M, 30 mL) and NaCl (*aq. sat.*, 30 mL), dried over MgSO₄ and the solvent was evaporated *in vacuo*. Purification was carried out by FC (CH₂Cl₂/acetone 3:1 → 1:1) and afforded

the desired product as a colorless solid (3.07 g, 2.31 mmol, 73%).

Mp.: 131 °C. IR (neat): 3294*br m*, 2972*m*, 1755*w*, 1633*s*, 1538*s*, 1455*m*, 1365*m*, 1305*m*, 1206*s*, 1174*s*, 1062*m*, 993*w*, 915*w*, 853*m*, 735*s*, 701*m*, 570*w*. ¹H-NMR (300 MHz, CDCl₃): δ = 7.78 (*d*, *J* = 8.1 Hz, 4 H, 4 × Aryl-*H*), 7.48 (*br s*, 1 H, CH₂CONH), 7.41 (*br s*, 1 H, NHCH₂CO₂), 7.32 - 7.30 (*m*, 5 H, 4 × Aryl-*H*, NHCH₂CO), 6.89 (*br s*, 2 H, 2 × CH₂NH), 5.77 (*br s*, 1 H, CO₂NH), 4.77 - 4.68 (*m*, 2 H, 2 × CHCH₃), 4.55 - 4.48 (*m*, 1 H, CH₂CONHCH), 4.14 - 4.08 (*m*, 1 H, CO₂NHCH), 4.03 - 3.84 (*m*, 4 H, 2 × NHCH₂CO), 3.66 (*s*, 3 H, OCH₃), 3.48 - 3.34 (*m*, 4 H, 2 × CH₂CH₂NH), 3.21 - 2.95 (*m*, 4 H, 2 × CH₂N), 2.16 - 1.37 (*m*, 61 H, 2 × CH₂CH₂N, 2 × CH₂CH, 2 × CHCH₂CH₂, 8 × CH₂CH₃, 2 × CHCH₃, OC(CH₃)₃, 2 × NC(CH₃)₃), 1.08 - 0.94 (*m*, 12 H, 4 × CH₃), 0.83 - 0.59 (*m*, 12 H, 4 × CH₃). ¹³C-NMR (75 MHz, CDCl₃): δ = 173.7 (C), 172.7 (2 × C), 172.3 (C), 170.3 (C), 169.5 (C), 167.9 (2 × C), 156.4 (C), 147.8 (2 × C), 133.7 (2 × C), 127.2 (4 × CH), 127.0 (2 × CH), 126.7 (2 × CH), 82.7 (2 × CH), 80.4 (C), 73.8 (C), 73.4 (C), 62.9 (C), 62.7 (C), 57.3 (2 × C), 55.2 (CH), 53.3 (CH), 52.3 (CH₃), 47.1 (CH₂), 46.1 (CH₂), 43.5 (CH₂), 41.3 (CH₂), 39.6 (2 × CH₂), 34.8 (2 × CH₂), 33.6 (CH₂), 31.6 (CH₂), 31.4 (CH₂), 29.3 (2 × CH₂), 29.2 (2 × CH₂), 28.5 (3 × CH₃), 28.3 (6 × CH₃), 27.0 (CH₂), 26.7 (CH₂), 24.7 (2 × CH₂), 23.4 (2 × CH₃), 22.3

(CH₂), 11.8 (CH₃), 11.4 (CH₃), 9.7 (CH₃), 9.5 (2 × CH₃), 9.2 (CH₃), 8.4 (CH₃), 7.8 (CH₃). MS (ESI): 688 [M+2Na]²⁺, 1354 [M+Na]⁺. HRMS (ESI): calculated for C₇₂H₁₁₈N₁₀O₁₃Na⁺: 1353.8772, found: 1353.8782. Anal. calculated for C₇₂H₁₁₈N₁₀O₁₃×H₂O: C: 64.07, H: 8.96, N: 10.38. found: C: 64.37, H: 8.97, N: 10.27.

Boc-bis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl)-benzamide)-Gly]-OH (37)




NaOH (*aq.*, 0.25 M, 15 mL) was added to a solution of tetrapeptide **17** (450 mg, 0.34 mmol, 1.0 eq.) in MeOH (25 mL). The reaction mixture was stirred for 16 h at rt. HCl (*aq.*, 1 M, 10 mL) was added and the mixture was extracted with CH₂Cl₂ (4 × 30 mL). The combined organic phases were dried over MgSO₄ and the solvent was removed *in vacuo*. Acid **37** was obtained as a colorless solid (436 mg, 330 μmol, 97%).

Mp.: 146 °C. IR (neat): 3444*br w*, 2973*m*, 2481*br w*, 1638*s*, 1570*w*, 1456*s*, 1366*m*, 1246*w*, 1205*m*, 1170*m*, 1065*w*, 1016*w*, 855*w*, 769*w*, 707*w*, 470*m*. ¹H-NMR (400 MHz,

CD₃OD): δ = 7.82 (*d*, *J* = 7.7 Hz, 4 H, 4 × Aryl-*H*), 7.44 - 7.39 (*m*, 4 H, 4 × Aryl-*H*), 4.87 - 4.77 (*m*, 2 H, 2 × CHCH₃), 4.43 (*dd*, *J*₁ = 5.0 Hz, *J*₂ = 8.7 Hz, 1 H, NHCHCO), 4.05 - 3.99 (*m*, 1 H, NHCHCO), 3.94 - 3.83 (*m*, 4 H, 2 × NHCH₂CO), 3.40 (*t*, *J* = 5.9 Hz, 4 H, 2 × CH₂CH₂N), 3.30 - 3.07 (*m*, 4 H, 2 × CH₂N), 2.17 - 1.29 (*m*, 61 H, 2 × CH₂CH₂N, 2 × CH₂CH, 2 × CHCH₂CH₂, 8 × CH₂CH₃, 2 × CHCH₃, OC(CH₃)₃, 2 × NC(CH₃)₃), 1.14 - 1.01 (*m*, 12 H, 4 × CH₃), 0.89 - 0.80 (*m*, 6 H, 2 × CH₃), 0.73 - 0.63 (*m*, 6 H, 2 × CH₃). ¹³C-NMR (100 MHz, CD₃OD): δ = 175.9 (C), 174.7 (C), 174.6 (C), 174.4 (C), 172.6 (C), 171.5 (C), 169.9 (2 × C), 158.0 (C), 149.0 (C), 148.8 (C), 147.6 (C), 135.0 (C), 134.9 (C), 129.5 (CH), 128.6 (CH), 128.5 (CH), 128.3 (2 × CH), 127.8 (CH), 127.5 (CH), 127.2 (CH), 83.9 (CH), 83.7 (CH), 74.6 (C), 74.1 (C), 63.8 (C), 63.5 (C), 58.6 (C), 56.3 (CH), 54.5 (CH), 47.3 (CH₂), 43.7 (CH₂), 41.8 (CH₂), 40.7 (CH₂), 40.5 (CH₂), 36.0 (CH₂), 34.7 (CH₂), 32.5 (CH₂), 30.4 (CH₂), 30.2 (CH₂), 30.1 (2 × CH₂), 29.9 (CH₂), 28.7 (3 × CH₃), 28.4 (6 × CH₃), 27.8 (2 × CH₂), 27.6 (CH₂), 27.0 (CH₃), 25.7 (2 × CH₂), 24.1 (2 × CH₂), 23.5 (CH₃), 22.4

(CH₃), 20.8 (CH₃), 12.1 (CH₃), 11.7 (CH₃), 9.9 (CH₃), 9.7 (CH₃), 9.6 (CH₃), 8.7 (CH₃), 8.1 (CH₃). MS (ESI): 681 [M+2Na]²⁺, 1340 [M+Na]⁺. HRMS (ESI): calculated for C₇₁H₁₁₆N₁₀O₁₃Na⁺: 1339.8616, found: 1339.8587.

HCl·H-Bis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl)-benzamide)-Gly]-OMe (38)




Tetrapeptide **17** (1.00 g, 0.75 mmol, 1.0 eq.) was added to a methanolic solution of HCl (1.25 M in MeOH, 3.00 mL, 3.75 mmol, 5.0 eq.) and the resulting mixture was stirred for 16 h at rt. The solvent was evaporated *in vacuo* and amine hydrochloride **38** was obtained as a colorless solid (0.95g, 0.75 mmol, 100%).

Mp.: 110 °C. IR (neat): 3313*br w*, 2970*m*, 2938*m*, 2363*w*, 1746*w*, 1652*s*, 1544*s*, 1459*s*, 1367*m*, 1309*m*, 1225*m*, 1122*m*, 952*w*, 855*w*, 762*w*, 671*w*. ¹H-NMR (300 MHz, CD₃OD): δ = 7.85 - 7.80 (*m*, 4 H, 4 × Aryl-*H*), 7.45 - 7.41 (*m*, 4 H, 4 × Aryl-*H*), 4.84 - 4.77 (*m*, 2 H, 2 × CHCH₃), 4.43 (*dd*,

$J_1 = 5.3$ Hz, $J_2 = 8.6$ Hz, 1 H, CHCO), 4.12 - 3.84 (*m*, 5 H, CHCO, 2 × NHCH₂CO), 3.72 (*s*, 3 H, OCH₃), 3.47 - 3.39 (*m*, 4 H, 2 × CH₂CH₂N), 3.24 - 3.07 (*m*, 4 H, 2 × CH₂N), 2.19 - 1.32 (*m*, 52 H, 2 × CH₂CH₂N, 2 × CH₂CH, 2 × CHCH₂CH₂, 8 × CH₂CH₃, 2 × CHCH₃, 2 × NC(CH₃)₃), 1.15 - 1.01 (*m*, 12 H, 4 × CH₃), 0.88 - 0.80 (*m*, 6 H, 2 × CH₃), 0.73 - 0.64 (*m*, 6 H, 2 × CH₃). ¹³C-NMR (100 MHz, CD₃OD): δ = 174.7 (C), 174.6 (C), 171.5 (C), 171.0 (C), 170.9 (C), 169.9 (C), 149.2 (C), 149.1 (2 × C), 149.0 (C), 135.0 (C), 134.9 (C), 134.7 (C), 134.6 (C), 128.3 (4 × CH), 127.9 (4 × CH), 84.0 (2 × CH), 74.7 (C), 74.3 (C), 63.9 (CH), 58.7 (2 × C), 54.5 (CH), 52.7 (CH₃), 48.3 (CH₂), 47.5 (CH₂), 43.4 (CH₂), 41.8 (2 × CH₂), 40.7 (CH₂), 40.4 (CH₂), 36.0 (CH₂), 32.7 (CH₂), 32.1 (CH₂), 30.2 (2 × CH₂), 30.0 (2 × CH₂), 28.4 (6 × CH₃), 27.9 (CH₂), 27.7 (CH₂), 25.9 (CH₂), 25.8 (CH₂), 24.1 (CH₂), 23.5 (CH₃), 23.3 (CH₂), 22.4 (CH₃), 12.2 (CH₃), 11.8 (CH₃), 9.9 (CH₃), 9.8 (CH₃), 9.7 (2 × CH₃), 8.6 (CH₃), 8.1 (2 × CH₃). MS (ESI): 627 [M+Na+H]²⁺, 1232 [M+H]⁺, 1254 [M+Na]⁺. HRMS (ESI): calculated for C₆₇H₁₁₀N₁₀O₁₁Na⁺: 1253.8248, found: 1253.8250.


Boc-tetrakis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl)-benzamide)-Gly]-OMe (18)



Acid **37** (200 mg, 150 μmol , 1.0 eq.) and amine hydrochloride **38** (192 mg, 150 μmol , 1.0 eq.) were dissolved in DMF (2.5 mL). EDCI (44.0 mg, 230 μmol , 1.5 eq.), HOBt (28.0 mg, 180 μmol , 1.2 eq.) and NMM (42.0 μL , 400 μmol , 2.5 eq.) were added and the reaction mixture was stirred for 16 h at rt. The solvent was removed under reduced pressure and the crude product was purified by RP-FC ($\text{H}_2\text{O} \rightarrow \text{H}_2\text{O}/\text{MeOH} 1:1 \rightarrow \text{H}_2\text{O}/\text{MeOH} 1:4 \rightarrow \text{H}_2\text{O}/\text{MeOH} 1:9 \rightarrow \text{MeOH}$). Octapeptide **18** was obtained as a colorless solid (256 mg, 10.1 μmol , 67%).

Mp.: Decomp. above 230 $^\circ\text{C}$. IR (neat): 3283 $br w$, 2970 w , 2928 w , 1624 s , 1538 s , 1455 m , 1365 m , 1305 m , 1207 m , 1175 m , 1152 m , 1062 m , 933 w , 940 w , 914 w , 853 m , 768 w , 685 m . MS (ESI): 1288 $[\text{M}+2\text{Na}]^{2+}$, 2553 $[\text{M}+\text{Na}]^+$. HRMS (ESI): calculated for $\text{C}_{138}\text{H}_{224}\text{N}_{20}\text{O}_{23}\text{Na}_2^{2+}$: 1287.8379, found: 1287.8414. Due to low solubility of **18** in common solvents we did not obtain NMR-Spectra.

Boc-tetrakis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly]-OH (39)




Octapeptide **18** (127 mg, 50.0 μmol , 1.0 eq.) was dissolved in MeOH (300 mL) under ultrasonification. NaOH (*aq.*, 1 M, 20 mL) was added and the reaction mixture was stirred for 40 h at rt. Formic acid (2.5 mL) was added and the solvent removed under reduced pressure. The crude product was purified by RP-FC (H_2O (200 mL) \rightarrow MeOH). Acid **39** was isolated as a colorless solid (118 mg, 46.9 μmol , 94%).

Mp.: Decomp. above 230 $^\circ\text{C}$. IR (neat): 3296 $br\ w$, 2971 m , 2930 m , 2880 m , 1639 s , 1539 s , 1456 m , 1365 m , 1307 m , 1244 m , 1206 m , 1150 m , 1062 m , 1018 m , 993 m , 938 w , 915 w , 854 m , 767 m , 696 m . MS (ESI): 1281 $[\text{M}+2\text{Na}]^{2+}$. HRMS

(ESI): calculated for $\text{C}_{137}\text{H}_{222}\text{N}_{20}\text{O}_{23}\text{Na}_2^{2+}$: 1280.8301, found: 1280.8309. Due to low solubility of **39** in common solvents we did not obtain NMR-Spectra.

HCl·H-Tetrakis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl]-benzamide)-Gly]-OMe (40)




Octapeptide **18** (127 mg, 50.0 μmol , 1.0 eq.) was suspended in MeOH (5 mL) and a methanolic solution of HCl (1.25 M in MeOH, 500 μL , 630 μmol , 12.5 eq.) was added. The reaction mixture was stirred for 48 h at rt and the volatile components were removed *in vacuo*. Amine hydrochloride **40** was obtained as a colorless solid (123 mg, 50.0 μmol , 100%).

Mp.: Decomp. above 195 $^\circ\text{C}$. IR (neat): 3286 $br\ w$, 2971 m , 2937 m , 2879 w , 1639 s , 1538 s , 1503 s , 1456 m , 1413 m , 1364 m , 1306 s , 1281 m , 1205 s , 1150 m , 1063 m , 1017 w , 994 w , 940 w ,

915 m , 854 m , 768 w . MS (ESI): 1227 [M+Na+H]²⁺, 1238 [M+2Na]²⁺, 2453 [M+Na]⁺. HRMS (ESI): calculated for C₁₃₃H₂₁₆N₂₀O₂₃HNa²⁺: 1226.8207, found: 1226.8204. Due to low solubility of **40** in common solvents we did not obtain NMR-Spectra.

Boc-octakis[Lys(4-[1-{1-*tert*-butyl-3,3,5,5-tetraethylpiperazin-2-one-1-yloxy}-ethyl)-benzamide)-Gly]-OMe (19)



Acid **39** (112 mg, 44.5 μ mol, 1.0 eq.) and amine hydrochloride **40** (110 mg, 44.5 μ mol, 1.0 eq.) were dissolved in *N*-methylpyrrolidinone (2.5 mL). HATU (25.0 mg, 65.7 μ mol, 1.5 eq.), HOAt (9.00 mg, 67.0 μ mol, 1.5 eq.) and DIPEA (39.0 μ L, 220 μ mol, 5.0 eq.) were added and the reaction mixture was stirred for 16 h at rt. Acetone (10 mL) and MeOH (10 mL) were added and the product was crystallized at 4 °C. The crystallization process was repeated once and the desired product was obtained as a colorless solid (121 mg, 24.4 μ mol, 55%).

Mp.: Decomp. above 210 °C. IR (neat): 3292 m , 2969 w , 2937 w , 2881 w , 1700 w , 1626 s , 1517 s , 1437 m , 1411 m , 1363 w , 1302 m , 1262 m , 1208 m , 1147 m , 1063 s , 1014 s , 913 m , 852 m , 804 m . HRMS (ESI): calculated for C₂₇₀H₄₃₆N₄₀O₄₃: 4927.31600. found: 4927.32243, calculated from: 1233.58752 [M+4H]⁴⁺, 1644.44763 [M+3H]³⁺.

Polymerization procedures

General procedure for the polymerization of styrene with initiators 1, 9, 11, 13, 14


In a *Schlenk*-tube the peptide initiator (0.125 mol% to 1.0 mol%) was suspended in styrene (250 μ L, 2.19 mmol, 1.0 eq.). The suspension was degassed by three freeze-thaw cycles under cooling in liquid nitrogen. The reaction mixture was heated in an oil bath at 125 °C for the desired time. The tube was cooled to rt, the polymer was dissolved in CH₂Cl₂ and transferred to an open flask. Unreacted monomer was removed in a vacuum cabinet for at least 18 h at 60 °C. Conversion was determined gravimetrically. Theoretical molecular weight ($M_{n,theo.}$) was calculated from yield. Experimental molecular weight ($M_{n,exp.}$) and polydispersity index (PDI) were determined by GPC.

General procedure for the polymerization of NIPAM with initiators 16, 17, 18, 19


The peptide initiator (0.5 mol% or 1.0 mol%) was suspended in benzene (1 mL) and NIPAM (201 mg, 1.78 mmol, 1.0 eq.) was added. Argon was passed through this suspension via a syringe for 1 min. The tube was sealed tightly and heated at 125 °C in an oil bath for the desired time. After cooling to rt, the mixture was dissolved in a small amount of acetone and the polymer was precipitated by the addition of diethylether. Conversion was determined gravimetrically. Theoretical molecular weight ($M_{n,theo.}$) was calculated from yield. Experimental molecular weight ($M_{n,exp.}$) and polydispersity index (PDI) were determined by GPC.

$^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra of new compounds


$^1\text{H-NMR}$ spectrum of 28




$^{13}\text{C-NMR}$ spectrum of 28




¹H-NMR spectrum of 7




¹³C-NMR spectrum of 7




¹H-NMR spectrum of 1




¹³C-NMR spectrum of 1




¹H-NMR spectrum of 8b




¹³C-NMR spectrum of 8b




¹H-NMR spectrum of 8a




¹³C-NMR spectrum of 8a




¹H-NMR spectrum of 9




¹³C-NMR spectrum of 9




¹H-NMR spectrum of 10b




¹³C-NMR spectrum of 10b




¹H-NMR spectrum of 10a




¹³C-NMR spectrum of 10a




¹H-NMR spectrum of 34




¹³C-NMR spectrum of 34




¹H-NMR spectrum of 16




¹³C-NMR spectrum of 16




¹H-NMR spectrum of 35




¹³C-NMR spectrum of 35




¹H-NMR spectrum of 36




¹³C-NMR spectrum of 17




¹H-NMR spectrum of 37




¹³C-NMR spectrum of 37



¹H-NMR spectrum of 38



¹³C-NMR spectrum of 38



Polymerization results

Polymerization of styrene, T = 125 °C, neat, sealed tube.

Entry	Initiator	Conc. (mol%)	Time (h)	Conv. (%)	M _{n,th} (g/mol)	M _{n,exp} (g/mol)	PDI
1	1	0,125	1	10	9300	10100	1,20
2	1	0,25	1	6	2900	2600	1,20
3	1	1,0	3	15	2200	2400	1,11
4	1	0,5	6	16	4000	5700	1,19
5	1	1,0	6	24	3000	3200	1,15
6	1	0,5	12	48	10600	9500	1,08
7	1	1,0	12	40	4800	5500	1,09
8	1	0,5	24	64	13800	11400	1,10
9	1	1,0	24	56	6400	5000	1,11
10	9	0,25	3	12	6100	7100	1,15
11	9	0,5	3	19	4900	5000	1,13
12	9	0,25	12	48	25500	22300	1,16
13	9	0,5	12	42	9800	8800	1,18
14	9	0,25	24	72	31000	25000	1,12
15	9	0,5	24	62	13900	11200	1,16
16	11	0,125	3	23	21500	18900	1,08
17	11	0,25	3	16	8700	8100	1,08
18	11	0,125	9	42	36900	32000	1,08
19	11	0,125	12	53	45800	29600	1,08
20	11	0,25	12	59	26500	24900	1,08
21	11	0,125	24	64	55200	31200	1,07
22	11	0,25	24	62	22600	22900	1,09
23	13	0,083	3	24	33300	21200	1,08
24	13	0,167	3	27	20000	17000	1,07
25	13	0,083	12	51	65600	95200	1,06
26	13	0,167	12	43	29800	33100	1,06
27	14	0,008	1	13	177300	131700	1,22
28	14	0,008	2	22	294200	297500	1,30
29	14	0,016	0,5	9	62000	64300	1,18
30	14	0,016	1	15	103700	87100	1,14
31	14	0,016	3	22	150600	70700	1,15
32	14	0,031	0,5	7	28800	30300	1,19
33	14	0,031	1	16	56400	37000	1,14

Polymerization of NIPAM, at 125 °C, 1.78 M in benzene, sealed tube.

Entry	Initiator	Conc. (mol%)	Time (h)	Conv. (%)	$M_{n,th}$ (g/mol)	$M_{n,exp}$ (g/mol)	PDI
1	16	0,5	6	24	6100	10000	1,21
2	16	1,0	6	15	2500	6900	1,17
3	16	0,5	12	33	8100	11400	1,19
4	16	1,0	12	38	5000	7400	1,18
5	16	0,5	24	56	13500	20200	1,12
6	16	1,0	24	76	9300	12600	1,20
7	17	0,25	3	19	10000	9400	1,25
8	17	0,5	3	16	5000	5900	1,20
9	17	0,25	6	27	13700	12200	1,24
10	17	0,5	6	21	6200	8200	1,18
11	17	0,25	12	43	20900	20700	1,14
12	17	0,5	12	37	9700	10300	1,17
13	17	0,25	24	64	30200	26500	1,14
14	17	0,5	24	71	17400	19500	1,14
15	18	0,125	3	21	21800	17500	1,16
16	18	0,25	3	25	13600	12100	1,17
17	18	0,125	6	31	30500	28500	1,10
18	18	0,25	6	29	15700	21200	1,10
19	18	0,125	12	44	42700	37600	1,13
20	18	0,25	12	46	23100	23800	1,11
21	18	0,125	24	57	54300	45500	1,09
22	18	0,25	24	74	35700	33600	1,11
23	19	0,063	1	23	44300	47900	1,22
24	19	0,125	1	33	35500	36600	1,24
25	19	0,063	2	33	64500	49800	1,20
26	19	0,125	2	44	40000	39000	1,18
27	19	0,063	6	50	96400	53600	1,19
28	19	0,125	6	71	70000	43400	1,20
29	19	0,063	12	73	138200	98300	1,52
30	19	0,125	12	78	76400	43400	1,20
31	19	0,063	24	85	160100	149300	2,40
32	19	0,125	24	87	84500	85900	1,78

Proof of livingness of polymerizations

The controlled character of styrene polymerizations mediated by initiator **9**

Initiator **9** was used in the general polymerization procedure for styrene with a concentration of 0.5 mol% for 3, 6, 12, 18 and 24 h respectively. Conversion was determined as a function of time and the molecular weight and analyzed as a function of monomer conversion. Both plots show a typical linear behavior as expected for a controlled process.




Figure 1: Monomer conversion vs. time (styrene, initiator **9**, 0.5 mol%, 125 °C).




Figure 2: $M_{n,exp.}$ vs. monomer conversion (styrene, initiator **9**, 0.5 mol%, 125 °C).

Proof of control/livingness of NIPAM polymerizations using initiator **17**

NIPAM polymerization was carried out in the described manner with initiator **17** with a concentration of 0.5 mol% with respect to NIPAM at 125 °C for 3, 6, 9, 12 and 24 h. Conversion was determined as a function of time and the molecular weight and analyzed as a function of monomer conversion. Both plots show a typical linear behavior as expected for a controlled process.




Figure 3: Monomer conversion vs. time (NIPAM, initiator **17**, 0.5 mol%, 125 °C).




Figure 4: Molecular weight vs. conversion (NIPAM, initiator **17**, 0.5 mol%, 125 °C).

DLS-data of peptide-PNIPAM conjugates

Temperature [°C]	n = 1		n = 2		n = 4		n = 8	
	V _(max) [nm]	n _(max) [nm]						
10	-	-	4.50	3.93	6.43	5.23	11.83	8.88
12	-	-	4.28	3.68	5.98	4.88	12.10	9.36
14	-	-	4.42	3.86	55.08	42.88	12.19	9.60
16	3.07	2.31	4.28	3.68	79.02	63.25	11.87	9.08
18	3.44	2.71	4.32	3.77	109.4	90.73	11.71	8.87
20	3.63	2.97	320.6	252.8	148.8	125.5	11.72	8.83
21	3.66	3.15	488.1	426.6	-	-	11.85	9.02
22	3.91	3.48	569.9	494.9	183.9	157.7	12.36	9.13
23	89.5	69.5	644.3	594.6	-	-	54.69	40.62
24	111.3	89.4	672.3	625.8	207.2	172.0	83.60	66.76
25	168.0	130.1	701.7	649.0	-	-	107.5	88.49
26	234.6	185.2	738.0	676.2	213.7	181.8	116.6	98.15
27	346.0	233.2	750.6	687.6	-	-	-	-
28	437.7	260.9	802.2	711.4	218.6	176.3	130.0	110.0
29	497.4	265.8	814.2	727.6	-	-	-	-
30	503.7	386.8	843.9	757.8	212.8	175.4	128.8	108.1
32	536.9	366.0	899.2	737.4	212.1	176.2	125.2	106.4
34	708.1	338.9	905.3	768.2	216.2	173.5	124.7	106.0

All samples were measured with a concentration of 1 mg/mL of the conjugate in water. Between the measurements, samples were equilibrated for 5 minutes at the determined temperature.

References

- [1] M. K. W. Choi, H. S. He and P. H. Toy, *J. Org. Chem.*, 2003, **68**, 9831.
- [2] K. Matyjaszewski, *Macromolecules*, 1998, **31**, 5955.
- [3] M. Stasiak, C. Röben, N. Rosenberger, F. Schleth, A. Studer, A. Greiner and J. H. Wendorff, *Polymer*, 2007, **48**, 5208.
- [4] T. Kakuchi, A. Narumi, Y. Miura, S. Matsuya, N. Sugimoto, T. Satoh and H. Kaga, *Macromolecules*, 2003, **36**, 3909.
- [5] S. Miele, P. Nesvadba and A. Studer, *Macromolecules*, 2009, **42**, 2419.
- [6] S. Miele, *Synthese, Strukturierung und Anwendung von Polymerbürsten*, 2009, Dissertation, Westfälische-Wilhelms Universität Münster, Germany.